Moffitt logo

Clinical Trials Search

Clinical Trial 20760

Cancer Type: Gastrointestinal Tumor
Study Type: Treatment
NCT#: NCT04404595

Phase: Phase I
Prinicipal Investigator: Dae Won Kim

Call 813-745-6100
or 1-800-679-0775 Learn More
Overview

Study Title

Open-Label, Multicenter, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin18.2 Chimeric Antigen Receptor T-Cell Therapy in Patients with Advanced Gastric or Pancreatic Adenocarcinoma

Summary

This is an open label, multi-center, Phase 1b clinical trial to evaluate the safety and efficacy of autologous claudin18.2 chimeric antigen receptor T-cell therapy in patients with advanced gastric or pancreatic adenocarcinoma.

Objective

Cohort A Primary -Evaluate the safety and tolerability of CAR-CLDN18.2 T-cell therapy (CT041) in patients with advanced STAD or PAAD -Identify the MTD and a RP2D of CT041 therapy in patients with STAD or PAAD Secondary: -Evaluate clinical efficacy outcomes with CAR-CLDN18.2 T-cell therapy (CT041) in patients with advanced STAD or PAAD Exploratory: -Evaluate PK and biodistribution of CAR-CLDN18.2 T-cell therapy (CT041) in patients with STAD or PAAD -Evaluate the performance of CLDN18.2 IHC assay in patients with STAD or PAAD -Evaluate anti-CAR-CLDN18.2 T-cell therapy (CT041) drug antibodies in patients with STAD or PAAD Cohort B Primary: -Determine the efficacy of CAR-CLDN18.2 T-cell therapy (CT041), in terms of ORR in patients with PAAD Secondary -Evaluate the safety and tolerability of CAR-CLDN18.2 T-cell therapy (CT041) in patients with PAAD -Evaluate additional clinical efficacy outcomes with CAR-CLDN18.2 T-cell therapy (CT041) in patients with PAAD Exploratory -Evaluate PK and biodistribution of CAR-CLDN18.2 T-cell therapy (CT041) in patients with PAAD -Evaluate the performance of CLDN18.2 IHC assay in patients with PAAD -Evaluate anti-CAR-CLDN18.2 T-cell therapy (CT041) drug antibodies in patients with PAAD

Treatments

Therapies

Medications

CT041 (); Nab-paclitaxel (Abraxane); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

Inclusion Criteria

  • Voluntarily signed the ICF
  • Age >18 and > Must have CLDN18.2-positive tumor expression as determined by the CLDN18.2 IHC assay; Age > 18 and > Estimated life expectancy > 12 weeks
  • At least 1 measurable lesion per RECIST 1.1
  • ECOG performance status of 0 or 1
  • Sufficient venous access for leukapheresis collection and no other contraindications to leukapheresis
  • Patients should have reasonable CBC counts, renal and hepatic functions
  • Women of childbearing age must undergo a serum pregnancy test with negative results before screening and infusion and be willing to use effective and reliable method of contraception
  • Men must be willing to use effective and reliable method of contraception for at least 6 months after T-cell infusion

  • Exclusion Criteria

  • Pregnant or lactating women
  • HIV, active hepatitis C virus (HCV), or active hepatitis B virus (HBV) infusion
  • Any uncontrolled active infection
  • AEs from previous treatment that have not recovered
  • Patients who have clinically significant thyroid dysfunction
  • Patients allergic to any drugs of the preconditioning regimen, tocilizumab, dimethyl sulfoxide (DMSO), or CT041 CAR-CLDN18.2 T-cell
  • Patients who have received prior cellular therapy such as (CAR T, TCR, tumor-infiltrating lymphocytes) or organ transplantation; Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression
  • Patients with heavy tumor burden such as significant lung disease
  • Unstable/active ulcer or digestive tract bleeding or recent digestive surgery that may have increased risk of bleeding
  • Patients who have a history of esophageal or gastric resection with increased risk of bleeding or perforation
  • Patients requiring anticoagulant therapy such as warfarin or heparin
  • Patients requiring long-term antiplatelet therapy
  • Use of prednisone or other equivalent within 14 days before leukapheresis or preconditioning
  • Anticancer treatment within approximately 2 weeks prior to leukapheresis or approximately 3 weeks before preconditioning
  • Major surgery less than 1 week prior to leukapheresis or 3 weeks prior to preconditioning
  • Patients have clinical significant cardiac conditions that researchers believe that participating in this clinical trial may endanger the health of the patients
  • Patients have clinical significant pulmonary conditions
  • Patients known to have active autoimmune diseases
  • Patients with second malignancies in addition to STAD or PAAD
  • Patients have significant neurologic disorders
  • Patients are unable or unwilling to comply with the requirements of clinical trial.

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.